AU778729B2 - Method for determining care and prevention pathways for clinical management of wounds - Google Patents
Method for determining care and prevention pathways for clinical management of wounds Download PDFInfo
- Publication number
- AU778729B2 AU778729B2 AU29681/00A AU2968100A AU778729B2 AU 778729 B2 AU778729 B2 AU 778729B2 AU 29681/00 A AU29681/00 A AU 29681/00A AU 2968100 A AU2968100 A AU 2968100A AU 778729 B2 AU778729 B2 AU 778729B2
- Authority
- AU
- Australia
- Prior art keywords
- wound
- decision tree
- visual
- factors
- visual decision
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010052428 Wound Diseases 0.000 title claims description 241
- 208000027418 Wounds and injury Diseases 0.000 title claims description 241
- 238000000034 method Methods 0.000 title claims description 37
- 230000002265 prevention Effects 0.000 title claims description 19
- 230000037361 pathway Effects 0.000 title description 7
- 230000000007 visual effect Effects 0.000 claims description 109
- 238000003066 decision tree Methods 0.000 claims description 86
- 238000011282 treatment Methods 0.000 claims description 41
- 230000002452 interceptive effect Effects 0.000 claims description 27
- 210000000416 exudates and transudate Anatomy 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 20
- 238000012502 risk assessment Methods 0.000 claims description 18
- 230000009471 action Effects 0.000 description 51
- 239000000047 product Substances 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 17
- 235000016709 nutrition Nutrition 0.000 description 13
- 238000007726 management method Methods 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- 230000001338 necrotic effect Effects 0.000 description 10
- 208000004210 Pressure Ulcer Diseases 0.000 description 9
- 230000002358 autolytic effect Effects 0.000 description 9
- 238000001804 debridement Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002745 absorbent Effects 0.000 description 8
- 239000002250 absorbent Substances 0.000 description 8
- 206010011985 Decubitus ulcer Diseases 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 206010021639 Incontinence Diseases 0.000 description 6
- 206010030124 Oedema peripheral Diseases 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 239000011250 protective ointment Substances 0.000 description 6
- 206010060708 Induration Diseases 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 238000003287 bathing Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000416 hydrocolloid Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 235000005974 protein supplement Nutrition 0.000 description 5
- 229940116540 protein supplement Drugs 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000000429 Factor XII Human genes 0.000 description 3
- 108010080865 Factor XII Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000021317 sensory perception Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000034347 Faecal incontinence Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000011496 polyurethane foam Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 229940041233 sensi-care protective barrier Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 101150067005 Sgk3 gene Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 229940109654 aloe vesta antifungal Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021191 food habits Nutrition 0.000 description 1
- 235000020803 food preference Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940090410 ilex skin Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229940088680 sensi-care Drugs 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Primary Health Care (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Psychiatry (AREA)
- General Business, Economics & Management (AREA)
- Signal Processing (AREA)
- Business, Economics & Management (AREA)
- Dermatology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Computation (AREA)
- Fuzzy Systems (AREA)
- Mathematical Physics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Description
1 Method for Determining Care and Prevention Pathways for Clinical Management of Wounds This applicationI is reiated io cu-pending application number 60/i 16,349 (filed January 19, 1999), which is incorporated herein by reference in its entirety.
The present invention relates to methods for consistently designating appropriate treatment protocols for patients, particularly protocols involving wounds or wound prevention.
A number of computer programs have been developed wherein a user, for example a care giver, inputs parameters indicative of a patient assessment into a computer and obtains a care plan as an output. Input parameters can include art recognized assessment parameters, such as those recommended by the National Pressure Ulcer Advisory Board. One example of such a 15 computer program is the Wound and Skin Intelligence System (WSIS) developed by Convatec and Applied Health Sciences. Other similar programs have been developed by Johnson Johnson Medical (a division of Ethicon, Inc.) and Smith Nephew, Ltd.
The effective use of such computer-based methods of deriving care 20 plans often requires simultaneous proximity of the care giver to both the patient and the computer. Care givers without ready access to a patient in close proximity to the programmed computer cannot effectively benefit from such .computer-based approaches. Moreover, even when the programmed computer is available, the practicalities of providing care often makes it awkward to input data prior to rendering a treatment protocol.
Accordingly, there is a need for a method of selecting care plans for patients customized to clinical assessment parameters that does not require immediate interaction with a computer, without compromising the quality of care provided. The present invention proves a method for correlating patient assessment parameters with appropriate treatment protocols. The method provides a visually keyed process to derive a care plan. The process does not require a computer, and when executed with a computer is highly integrated VVwith visual cues Such% a rocess can be embodied in devices that p;rovide WCSaKa u\specesAvw -uu.ooc la bedside tools to assist the care giver to make evidence-based decisions for the care of individuals, such as individuals at risk of forming wounds or individuals who already have wounds, such as a pressure ulcers.
The discussion of the background to the invention herein is inciuded to explain the context of the invention. This is not to be taken as an admission that any of the material referred to was published, known or part of the common general knowledge in Australia as at the priority date of any of the claims.
Throughout the description and claims of the specification the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.
W: \cisk@nkispecies\l29681-0.dc WO 0AI71A PCT/USl 001/01'%PT S- 2 Summary of the Invention In one embodiment, the invention relates to a method of identifying a wound care protocol for a given wound or wound prevention protocol appropriate for a given patient comprising: classifying the wound or patient against a defined scale for a first wound factor, which is defined wound assessment factor or defined wound risk assessment factor to obtain a wound classification; grading the wound or patient against defined scales for one or more second wound factors, which are wound assessment factors or wound risk assessment factors; and operating a visual decision tree device to show a decision or visual decision tree corresponding to the wound classification or to a scale for a wound assessment factor, wherein the visual decision tree device identifies at least one component of a treatment protocol for the graded wound factors. In some embodiments, at least one visual decision tree indicates two or more distinct decisions based on the grade of one or more second wound factors. In some embodiments, the visual decision tree is a mechanical device. In some embodiments, the method can also comprise providing an interactive visual scoring sheet on which markers for the available scores for two or more wound factors are displayed; and marking the appropriate score for the two or more wound factors on the interactive visual scoring sheet, wherein the interactive visual scoring sheet contains a marker associated with one or more of the scores identifying an addition to the treatment protocol.
In some embodiments, the invention relates to a method comprising classifying the wound against a defined wound classification scheme; grading the wound against defined scales for one or more second wound assessment factors; and operating visual decision tree device to show a decision or visual decision tree corresponding to the wound classification or to a grade for a wound assessment factor, wherein at least one visual decision tree produced by the device dictates two or more distinct decisions based on the grade of one or more second wound assessment factors, and wherein the visual decision device identifies a treatment protocol for the wound classification and grades of the second wound assessment factors. In some embodiments of the invention, one of the two visual decision tree devices is selected based on wound classification, and the selected visual decision tree device is operated to show a decision or decision tree corresponding to a grade for exudate amount. In some embodiments, the wound W 0l0l/41"714 PCTIUS00/01274 classification scheme grades wounds from non-open or closed wounds, to wounds of various thicknesses, to wounds that cannot be graded due to obstructions.
The invention, in some embodiments, relates to a method of identifying a wound care protocol for a given wound or wound prevention protocol appropriate for a given patient comprising: classifying the wound or patient against a defined scale for a first wound factor, which is defined wound assessment factor or defined wound risk assessment factor to obtain a wound classification; grading the wound or patient against defined scales for one or more second wound factors, which are wound assessment factors or wound risk assessment factors; operating visual decision tree device to show the visual decision tree corresponding to the wound classification or to a scale for a wound assessment factor, wherein at least one visual decision tree dictates two or more distinct decisions based on the grade of one or more second wound factors, and wherein the visual decision tree device identifies at least one component of a treatment protocol for the graded wound factors; and marking a pre-defined display of treatment protocols to identify the components of a treatment protocol identified by the method. In some embodiments, the method of the invention is operated through a graphical user interface on an electronic processor, resulting in a display of treatment protocols that matches a printed display used in manual operations of the method.
The invention also relates to a visual decision tree device for identifying a wound care protocol for a given wound or wound prevention protocol appropriate for a given patient comprising: a mechanical or electronic device for identifying and displaying one of at least two decisions or visual decision trees based on one or more inputted wound factors according to a defined scale, wherein the visual decision tree device identifies at least one component of a treatment protocol for the graded wound factors. In some embodiments, the sliding card comprises markers corresponding to a defined scale for classifying the wound or patient. In some embodiments, one or more sliding cards shows a visual decision tree and wherein the housing comprises a view window through which one or more visual decision trees corresponding to the wound classification can be viewed. In some embodiments, the visual decision tree device is mechanical and wherein the slide card can be moved with respect to the housing to view through the view window any one of a plurality of individual decision trees displayed on the sliding card.
n A111AV1 A D~Tn 1~I1~ ,nl~ r* Uf f.fu 4 L II 3UUUII A- Brief Description of the Drawings Figure 1 displays a wound assessment interactive visual scoring sheet.
Figure 2 displays a chronic wound management decision tool, which is a type of portable mechanical slide-rule visual decision tree device.
Figure 2A displays a schematic of a slide-rule visual decision tree device.
Figure 2B displays a first set of two exemplary sliding cards.
Figure 2C shows a second set of two exemplary sliding cards.
Figure 3 displays a schematic of a modular wound care protocol sheet.
Figure 4 displays a Patient Risk Assessment and Nurse Action Record, which is a type of interactive visual scoring sheet.
Figure 5 displays a Patient Risk Assessment Evaluation Tool, which is a type of portable mechanical slide-rule decision tree device.
Figure 5B displays a third set of two exemplary sliding cards.
Figure 6 displays a modular wound prevention protocol sheet.
Figure 7 displays a Wound Care and Assessment Record.
Figure 8 displays a pressure ulcer pathway decision tool, which is a type of a portable mechanical slide-rule visual decision tree device.
Figure 9 displays a wound assessment interactive visual scoring sheet.
Figure 10 displays a chronic wound management decision tool, which is a type of portable mechanical slide-rule visual decision tree device.
Figure 11 displays a Wound Care and Assessment Record.
Detailed Description of the Invention FIG. 1 relates to an interactive visual scoring sheet 10 that can be used according to a preferred embodiment of the present invention. The interactive visual scoring sheet can take substantially the same visually-cued form on the screen of a computer or personal device assistant (PDA). In electronic form, each scoring choice is separately on a viewing screen represented as in the paper example illustrated in FIG. 1. The interactive visual scoring sheet 10 comprises a first defined scale 11 for classifying or grading a wound or patient according to a first wound factor 12 and a second defined scale 13 for classifying or grading the wound or patient for one or more second wound factors 14. In some embodiments, the second defined scale 13 can include classifying or grading of the wound or patient according to: a defined wound assessment factor, a D-rI InI 1 17A WU UU1/4114 defined wound risk assessment factor, some other classification of a patient's condition, or any combination of such factors. The first defined scale 11 and the second defined scale 13 can be represented by one or more markers 19 corresponding to one or more stages, grades or classifications. Markers 19 and associated criteria 15 can be indicated on the visual scoring sheet 10, for example, by indicia associated with markers 19, including varying colors, numbers, letters, symbols, texture or any combination thereof.
Optional associated criteria is provide a brief indication of the classifying or grading criteria. In some embodiments, the appropriate score for one or more classifying or grading factors can be marked on the interactive visual scoring sheet 10. The criteria can be indicated in whole or in part on the visual scoring sheet 10, or be referenced to criteria found elsewhere. The presence of at least a shorthand reference to the criteria is preferred. The second defined scales 13 can be with respect to one or more second wound factors 14. Second wound factors 14 can, in some embodiments, be selected from any number of factors including but not limited to: exudate amount, necrotic tissue amount, undermining, color of tissue around wound, granulating tissue, peripheral edema, peripheral induration and pain at wound. In some embodiments, second wound factors 14 can include, but are not limited to: sensory perception, moisture, activity, mobility, nutrition and friction shear. In some embodiments, as shown in FIG. 9, first wound factors 12 and second wound factors 14 can be selected from the group consisting of: depth, exudate amount, exudate type, necrotic tissue amount, necrotic tissue type, undermining, surrounding skin color, granulation, peripheral edema, peripheral induration, pain at wound, nutrition, infection, edges, epithelization, functional ability, compliance and healthy margin.
The exemplary wound grading factors selected for FIG. 1 are a subset of the exemplary wound grading factors selected for FIG. 9. The selection of the particular factors of FIG. I as sufficient to predict patient care protocols represents an embodiment of the invention.
In some embodiments, one or more of the markers 19 for the first wound factor 12 or second wound factor 14 pertaining to a wound or patient condition can be connected by connecting indicia 16 such as lines or arrows that identify one or more treatment protocol components 17. One or more treatment protocol components 17 may be correlated to one or more markers 19, for example by connecting indicia 16, and may he written or referred to on the interactive visual scoring sheet n nnA 171A 09-r/ I1 l I1 'A -6- The i!nteractive visual scoring sheet 10 can form, include or be used in reference to a visual decision tree 18. Exemplary decision trees 18 are shown in FIG. 2. The visual decision tree 18 can comprise connecting indicia 16. The visual decision tree 18 can dictate two or more distinct decisions based on one or both of the first or second defined scales 11, 13 to identify a treatment protocol component 17 for the classified or graded factors. In FIG. 2, a first set of markers 19a on a first sliding card 22a are used to indicate values or stages of the first or second defined scales 11, 13. A second set of markers 19b are used on a second sliding card 22b to indicate values or stages of the first or second defined scales 11, 13 in the example illustrated in FIG. 2.
In some embodiments, the first defined scale 11 can grade wounds from nonopen or closed wounds, to wounds of various thicknesses, to wounds that cannot be graded due to obstructions.
To assess a wound, the wound is first visually inspected and the particular wound or patient parameters are determined, for example, according to one or more defined scales for classifying or grading 11, 13. The wound or patient parameters can then be recorded by marking or indicating them on the interactive visual scoring sheet 10, for example by checking or circling appropriate markers 19. Connecting indicia 16 and a visual decision tree 18 can then be used to identify appropriate protocol components 17 corresponding to the indicated markers 19.
In one preferred embodiment of the invention depicted in FIG. 2, a visual decision tree device 20 is provided. A schematic of a visual decision tree device 20 is provided in FIG. 2A. In the nonlimiting example depicted in FIG. 2, the visual decision tree device 20 is a mechanical slide-rule device made up of a first housing 21A with a first view window 28A and a first sliding card 22a. Hingeably attached HINGE to the first housing 21A is second housing 21B into which slides a second sliding card 22b.
The user inputs a value for one or more first 12 or second 14 wound factors according to the markers 19a, 19b for the first or second defined scales 11, 13 displayed on the first or second sliding cards 22a, 22b, for example by adjusting the position of the appropriate sliding card 22a or 22b within the appropriate housing 21A or 21B such that an appropriate marker 19a or 19b corresponding to the desired input value is displayed in view. Selection of the appropriate housing 21A or 21B and slide card 22a or 22b is determined in this example by connecting indicia 16 to the "Classification of Wound" score n the vis-l ornrg sheet 10 of FG 1 WO 00/41714 ~~rm r r~ ~rr rn ~r 1 .WO 00./41714 7 rL IU"UUIUI 14 QUESTION 1 (FIG. 2A) identifies which first or second wound factor 12, 14 is used to identify the appropriate marker 19a. The display of the appropriate marker 19a aligns the appropriate decision or visual decision tree 18a-18d in the view window 28. If present, QUESTION 2 of the displayed visual decision tree identifies a marker 19b for which connecting indicia 16b identify appropriate wound care protocol components 17.
In some instances, such as illustrated decision tree 18c, the decision tree identifies the wound care protocol component 17 from the marker 19a.
Wound care protocol components 17 can be grouped in modules on a wound care protocol sheet 30, as shown in FIG 3. In some embodiments, protocol components 17 for wound care of wound prevention are grouped in alpha-numeric groups or modules 31 that correspond to decision tree 18 outcomes. Based on the decision tree 18 outcomes, one or more protocol components 17 may be followed. The modules 31 can be an alpha-numerically labeled module, can include goals for treatment, multiple alternative therapies and recommended products for treatment.
The schematic of FIG. 2A shows a two part visual decision tree devices comprising a housing 21 and a sliding card 22. The housing can comprise a top layer 23 and a bottom layer 24 made of, for example, heavy paper or plastic, joined along a top edge 25 and a bottom edge 26. A view window 28 is cut into the top layer 23. In some embodiments (not shown in FIG. 2A), the view window can be cut into the top layer or the bottom layer. The sides of the top layer 23 and the bottom layer 24 are left open to allow the sliding card 22 to be inserted and moved within the housing 21. The top layer 23 can have a question QUESTION 1 printed on it, which governs where the operator should slide the sliding card 22 so that the appropriate marker from a first set of markers 19a is indicated in the view window 28. The sliding card 22 is slid within housing 21 to a position with respect to the view window 28 where the QUESTION 1 on the top layer 23 is correctly answered by an appropriate marker 19a. A first set of connecting indicia 16a arrows) points to one or more values for a second set of markers 19b in response to QUESTION 2. The operator selects a value from the second set of markers 19b in response to a second question QUESTION 2 found on the sliding card 22 and performs the protocols (referenced as A, B or C in FIG. 2A at the bottom of the sliding card 22) that are indicated by a second set of arrows 16b.
In a particular example, the grade on first defined scale 11 on the interactive vis!a! scoring sheet 1 of FIG. 1 irentifies whether the slide rule of first housing 21 A or /I I nrf-'T /I IOJIA /ni ^1 VT.J UUI/1iI 8- PC I./uuuS00/012U the slide rule of second housing 21 B shall be used (FIG. Referring to second housing 21B of the visual decision tree device 20 of FIG. 2, the score for alpha second defined scale 13a identifies the position to which the ruler is adjusted. Referring to first and second s!iding cards 22a, 22h of FIG. 2 and FIG. 2C, in the first sliding card 22a, one dialed position on defined scale 13a for first sliding card 22a of FIG. 2C) gives a wound care protocol component 17 depending on the score of beta second defined scale 13c. Another dialed position on defined scale 13a for second sliding card 22b of FIG. 2C) depends on the score of delta second defined scale 13d. Two dialed positions or on defined scale 13a for first sliding card 22a of FIG. 2C) directly indicate wound care protocol components 17. Some dialed positions on the second sliding card depend on gamma second defined scale 13b. Referring to FIG. 1, additional wound care protocol components 17 are identified on the visual scoring sheet by connecting indicia 16 associated with first defined scale 11 and beta, epsilon, zeta, eta and theta wound care protocol components 13B, 13E-13H (FIG. Shown in FIGs.
2B and 2C are particular exemplary first slide and second slide cards 22c, 22d and 22a, 22b, (respectively). Some embodiments, for example as shown in FIG. 5 and FIG. can have a third sliding card 22e and a fourth sliding card 22f which can slide independently of each other to align a first marker 19a or a second marker 19b with a first view window 28a and a second view window 28b, respectively. These exemplary slide cards are shown in FIGs SB and 5C, respectively.
FIG. 2B and FIG. 2C display exemplary sets of first and second sliding cards 22a, 22b which can be used to practice the invention. The sliding cards 22a, 22b include separate visual decision trees 18e-181 that can be aligned with a view window of a housing. Likewise, FIG. 2C displays a set of first and second sliding cards 22a and 22b that include visual decision trees 18m-18t. For example, the first and second sliding cards 22c, 22d of FIG. 2B can be used in the visual decision tree device 20 of FIG. Likewise, the first and second sliding cards 22a, 22b of FIG. 2C can be used in the visual decision tree device 20 of FIG. 2. In FIG. 2B, first and second sliding cards 22c, 22d have markers 19a that correspond to a first defined scale 13a and markers 19b that correspond to one or more second defined scales 13b, 13c, 13d. Similarly, first and second sliding cards 22a, 22b of FIG. 2C have a first set of markers 19a corresponding to a first defined scale 13a, a second defined scale 13b, a third defined scale 13c and a fourth defin d scale 13d, which scales are defined for this example in the interactive 111f' l /A lW* I t~r n II\ ~~1 VVJ UUIII, #I 9 rLk IIU3VVIU I visual scoring sheet 10 of FIG. 1. The example displayed in FIG. 2C can be used in the visual decision tree decice 20 of FIG. 2.
In preferred embodiments, a patient data sheet 40 can be combined with an interactive visual scoring sheet 10 and a wound care protocol sheet 30 in a patient care into a patient diagnostic tool which can be, for example, a single double sided folder or folded sheet of paper. The patient diagnostic tool can be used in conjunction with one or more visual decision tree devices The invention can comprise any number of embodiments, some of which are described in the Figures. In some embodiments of the invention, the interactive visual scoring sheet can have different first defined scale 11 and different second defined scale 12 for wound classifying or grading or patient risk assessment. FIG. 1, FIG. 4 and FIG.
9 show different visual scoring sheets 10 that can be used to practice the invention. FIG.
2, FIG. 5, FIG. 8 and FIG. 10 show different visual decision tree devices 20 that can be used to practice the invention. FIG. 3 and FIG. 6 show different wound care protocol sheets 30 that can be used to practice the invention. FIG. 7 and FIG. 11 show different patient data sheets 40 that can be used to practice the invention. The figures are provided as examples of possible embodiments of elements which may be used to practice the invention, and should not be construed to limit the scope of the invention.
Definitions The following terms shall have, for the purposes of this application, the respective meaning set forth below.
interactive visual scoring sheet. An interactive visual scoring sheet is printed or electronic sheet on which scoring choices of wound factors are displayed in a form in which the scores can be visually marked.
matching electronic display. An electronic display of treatment protocols matches a traditionally printed display if the treatment options displayed match.
Sslide rule device. A mechanical visual decision tree device, which can include, for example, a slide rule or slide wheel device.
wn nn/Ai71A ~r nT r/1 h I l 10- rLIUUU/UILZ/4 visual decision tree. A visual decision tree is a representation of two or more decisions, with the appropriate decision indicated visually based on the score of at least one wound factor.
visual decision tree device. A visual decision tree device is a device, electrical or mechanical, which can provide a visual image of a decision or decision tree based on an inputted wound care or wound prevention assessment value. The device produces two or more separate visual images of a decision or decision tree, including at least one decision tree depending on the input value. With a mechanical device, such as a slide rule or slide wheel, "inputting" comprises adjusting the mechanical device to correspond to the input value.
9 wound factor. A wound factor is a wound assessment factor for which there is a defined grading scale or a wound risk assessment factor for which there is a defined grading scale.
The following examples further illustrate the present invention, but of course, should not be construed as in any way limiting its scope.
Example I Wound Treatment One example of a method for assessing the status of a patient and derivation of a care plan, or protocol, for wound treatment is as follows. A front cover of a Wound Care Assessment Record (FIG 7) can be completed and included to identify the patient and care giver and to record dates and details of treatment, or the like. A Wound Assessment Record (Pressure Sore Status Tool), a type of interactive visual scoring sheet (FIG. 1) is completed by circling appropriate assessment scores for each factor (exudate amount, necrotic tissue amount, undermining, surrounding skin color, granulation, peripheral edema, peripheral induration, and pain). Using the interactive visual scoring sheet of FIG. 1, a care giver, upon examining a wound, classifies the wound as Stage 3 according to the first defined scale for classification. The care giver then assigns the following scores to assessing the wound according to their respective second defined scale for grading the wound: Exudate amount 3; Necrotic Tissue Amount 3; Undermining 2; Color of Tissue Around Wound 3; Granulating Tissue 3; Peripheral Edema 1; Peripheral Induration 0; Pain at Wound 4.
I -1 l 1A ll "'IP I! Lk lA rvv~ UU,, II 11 rL IuO.uu ui'' Next, the Chronic Wound Management Pathway Decision Tool, a type of portable mechanical slide-rule visual decision tree device, of FIG. 2 is used as follows: using the Exudate Amount score selected from the interactive visual scoring sheet of FIG. 1. go to the colored side of the slide rule recommended; (ii) from the interactive visual scoring sheet of FIG. 1, identify the score checked for exudate amount and move the slide rule to the score for exudate amount; (iii) follow the arrows, answer all questions and select the appropriate nurse action items; circle the numbers in the Nurse Action Report (Care Plan), a type of modular wound care protocol (FIG. 3).
Accordingly, the care giver having assessed the wound, follows the decision tree provided in FIG. 1 and FIG. 2 to arrive at a care plan from FIG. 3. Following the wound assessment data detailed in the above example, this process is as follows. First, the caregiver notes that the marker for Stage 3 in the Classification of Wound scale has two arrows connected to it: a vertical arrow (which points to "See Red Side of Nurse Action Guide") and a horizontal arrow that passes through the marker pointing from left to right (which points to "Nurse Action The vertical arrow requires the care giver to consult the red side of the decision tool Nurse Action Guide), which corresponds to the top section of FIG. 2. Beginning at "START HERE" in the upper portion of the tool represented in FIG. 2, the care giver slides the card in the housing so that the number determined for Exudate Amount in the wound assessment is showing in the example). Once this is done, an arrow on the sliding card points to Nurse Actions 2 and 2C, which are found in FIG. 3, with accompanying text in Sections 2 and 2A of Table 1.
The care giver then follows the protocols corresponding to Nurse Actions 2 and 2C.
Returning to the interactive visual scoring sheet of FIG. 1, the care giver next visually notes all factors indicated that are intersected by a line with an arrow attached as an endpoint (necrotic tissue amount, surrounding skin color, granulation, peripheral edema, peripheral induration, pain at wound and nutrition). Ifa line attached to the box is checked or circled then the care giver follows through to the end of the arrow where one finds the appropriate nurse action referenced. The care giver then records the nurse action on the modular wound care protocol Nurse Action Report (Care Plan) of FIG. 3) by circling it. Ifa checked or circled box or marker does not have a line attached to it then the care giver is not required to do anything further for that marker. Finally, after circling all numbers on the modular wound care protocol FIG. the care giver follows the care plan and prnoceedc to take action.
WO 00/41714 -12- PCT/USOO/01274 Returning to the visual scoring sheet results in the above example, the horizontal arrow horizontally intersecting marker 3 for classification of wound and pointing to "Nurse Action 5" indicates that the care giver should also perform Nurse Action (which is found in Section 5 of Table 1).
Next, the care giver can examine each marker indicated in the grading scales (from "Exudate Amount" down to "Pain Wound") and look for horizontal arrows passing through a marker. For instance, the marker for indicated for "Necrotic Tissue Amount" has an arrow pointing to "Nurse Action Accordingly, the care giver would then perform the protocol for Nurse Action 3 (found in FIG. 3, with text in Section 3 of Table The results indicated above for "Granulating Tissue" and "Peripheral Edema" both require Nurse Action 4, however such multiple indications for any given Action do not increase the number of times the Action must be performed in this example, Nurse Action 4 is performed once, not twice). Finally, the marker for "Pain Wound" intersects an arrow that points to Nurse Action 6. Thus, in following the example above, the care giver would circle and perform Nurse Actions 2, 2C, 3, 4, and 5 as indicated in FIG. 3 by circles 32.
WO 00/41714 WO 0041714PCT/USOO/01274 14- Table 1, SECTION 2 *GOA* Obaina clan wund*GOAL* Absorb excess 2 2C exudate/maintain moist wound bed. environment.
Wound Cleansing Primary Dressing DSAF Clens Exudate Management Days Used M T W T F S S LIAQUAGEL Hydrofiber size F-1 Other Days Used M T W TEFS S Days Used M T W T F S S LIKaltostat Size Days UsedM T W T F S S 2 *GOAL* Provide moist wound LILyofoam Foam Dressing Size 2 e nvironment. Days UsedM T W T F S S PRODUCTS: DI Days UsedM T W T F S S Primary Dressing Secondary Dressing Moisture Retentive Dressing Moisture Retentive Dressing IDuoDERM CGF Size___L DuoDERM CGF Size Days Used M TWT FS S Days Used MT WT F SS LI Other Other Days Used M T W T F S S Days Used M T W T F S S Secondary Dressing Not applicable. PRODUCTS: 2 *GOAL* Assist in autolytic debridement and removal of necrotic tissue/ Provide moist wound environment.
PRODUCTS: Secondary Dressin2 Primay DresingMoisture Retentive Dressing Wound Hydration DoEMCFSz MI DuoDERM Hydroactive Gel Days Used M T W T F S S Days Used M T W T FS S Other Size__ 0I Other_____ Days Used M T1W TEFS S Days Used M T W T F S S WO 00/41714 13- PCT/USOO/01274 Table 1: Possible text for modular wound care protocol Sheet (FIG. 3) Table 1, SECTION 1 I |*GOAL* Maintain intact skin: Beware of deep tissue damage that may be j F Assess knowledge of patient/caregiver on risk of skin breakdown and methods of prevention.
Reduce effect of risk factors.
Pressure: regular repositioning and pressure distribution (pillows, devices) Shear/friction: Apply protective ointment or moisture retentive dressing to reduce friction Excess Moisture: Clean at routine intervals with a skin cleanser, pat dry.
Protect skin from moisture and irritants with a moisture barrier and/or absorbent dressings/absorbent products.
Dryness: Follow routine bathing procedure with gentle cleansers.
Moisturize immediately after bathing.
Apply body cream for areas prone to extreme dryness.
Trauma/Skin Tears: Apply protective coverings to protect against friction and/or pressure Nutrition altered: Nutritional Support Action Taken SKIN CARE PRODUCTS: Patient Bathing Aloe Vesta 2-n-1 Body Wash/Shampoo Days UsedM T W T F S S Sensi-Care Perineal/Skin Cleanser Days UsedM T W T F S S Aloe Vesta 2-n-1 Skin Perineal/Skin Cleanser Days Used M T W T F S S O- Other Days Used M T W T F S S Moisture Barriers Aloe Vesta 2-n-1 Protective Ointment Days UsedM T W T F S S Sensi-Care Protective Barrier Days UsedM T W T F S S O Other Days UsedM T W T F S S Skin Moisturizers Aloe Vesta 2-n-1 Skin Conditioner Days UsedM T W T F S S Sensi-Care Protective Barrier Days UsedM T W T F S S O Other Days UsedM T W T F S S Moisture Retentive Dressings O DuoDERM Extra Thin Days UsedM T W T F S Absorbent Dressings Lyofoam Days UsedM T W T F S Hydrosorb Days UsedM T W T F S Other Days UsedM T W T F S Protective Coverings Tubifast Days UsedM T W T F S El Tubipad Days UsedM T W T F S Arthropad Days UsedM T W T F S E" Other Days UsedM T W T F S Size
S
Size
S
Size
S
Size
S
S
S
S
S
.4-
L
Wl AAI171 A "T/1F IC i 0/12 7A Table 1, SECTIONS 3 AND 4 3 *GOAL* Reduce devitalized tissue.
PRODUCTS:
Debridement The suggested topical treatments will facilitate autolytic debridement. Autolytic debridement is usually not recommended for patients with infected wounds or patients at increased risk of infection.
O Surgical by MD 1 Nurse Enzymatic Days UsedM T W T F S S O Autolytic Mechanical Products Used 4 *GOAL* Identify infection and institute medicine treatment.
If infection is confirmed, perform Nurse Action 4A. If infection is not confirmed, perform Nurse Action 4B.
Nurse Action 4A: Appropriate medical treatment for infection should be initiated or continued. DuoDERM CGF dressings can be continued during the treatment of infection at the discretion of the clinician.
Nurse Action 4B: Evaluate for signs of infection. If not infected, moisture retentive dressing should extend beyond reddened area to protect skin.
Minimize friction and shear forces to surrounding skin.
Action Taken and Products Used to Treat Infection
PRODUCTS:
Primary Dressing Wound Hydration D DuoDERM Hydroactive Gel Days UsedM T W T F S S D Other Days UsedM T W T F S S Secondary Dressing Moisture Retentive Dressing DuoDERM CGF Size Days UsedM T W T F S S Other Size Days UsedM T W T F S S WO 00/41714 16- PCT/US00/01274 Tabic 1, SECTIONS 5 AND 6 *GOAL* .Prevent further skin breakdown and stimulate healing.
Relieve pressure PRESSURE ULCER Bed/Mattresses institute turning schedule for patient utilize pressure reduction device(s) Devices Action Taken and Products Used D Other VENOUS STASIS ULCER PRODUCTS: Compression Therapy E SurePressTM High Compression Bandage (30-40mm/Hg pressure to heal ulcer) F- SurePress Absorbent Padding D UNNA-FLEX Days Used M T W T F S S DIABETIC FOOT ULCERS Action Taken and Products Used Off loading of pressure 6 *GOAL* Pain Management Provide analgesics. Cover with Moisture Retentive Dressings.
Action Taken and Products Used WO 00/41714 17- PCT/USOO/01274 Table 2: Possible text for modular wound care protocol Sheet (FIG. 3) Nurse Action Report (Care Plan) Circle or check off the appropriate treatments and indicated products used.
Solutions for Would Treatment
L
Table 2, SECTION 1 1 *GOAL* Maintain intact skin: Beware of deep tissue damage that may be irreversible.
Assess knowledge of patient/caregiver on risk of skin breakdown and methods of prevention.
Reduce effect of risk factors.
Pressure: regular repositioning and pressure distribution (pillows, devices) Shear/friction: Apply Skin Care products (lubricate) or Moisture Retentive Dressing (reduce friction) Excess Moisture: Manage with Skin Care Products or Moisture Retentive Dressing (protection) and incontinence products Dryness: Use Skin Care bathing and protection products.
Nutrition altered: Nutritional Support Action Taken
PRODUCTS:
Patient Bathing Aloe Vesta Body Wash/Shampoo Days Used M T W T F S S O Septi-soft Body Wash/Shampoo Days UsedM T W T F S S O Other Days UsedM T W T F S S Skin Protection Aloe Vesta Skin Cream Days UsedM T W T F S S Aloe Vesta Protective Ointment Days Used M T W T F S S j Other Days UsedM T W T F S S Incontinence Care r Aloe Vesta Antifungal Ointment Days UsedM T W T F S S Aloe Vesta Protective Ointment Days UsedM T W T F S S O Aloe Vesta Perineal Foam Days UsedM T W T F S S C Aloe Vesta Perineal Solution Days UsedM T W T F S S Ilex Skin Protectant Paste Days UsedM T W T F S S Other Days UsedM T W T F S S WO 00/41714 18- PCT/US00/01274 Table 2, SECTIONS 2 and 3 Debride Necrotic Tissue 2 2 Debride necrotic tissue.
3 *GOAL* Provide systematic support/preventive measures to facilitate healing based on general patient assessment findings S Wound Cleansing. Moisture Retention PRODUCTS: Primary Dressing: Saline PRODUCTS: Days UsedM T W T F SS DuoD SAF C] DuoDERM CGF D SAF Clens Days UsedM T W T F S S Days UsedM T W T F S S E DuoDERM Extra Thin Othr DuoDERM Extra Thin SOther Days UsedM T W T F SS Days Used M T W T F S S Signadress Days UsedM T W T F S S Other Days Used M T W T F S S Secondary Dressing: N/A 3B 3C B Wound Hydration Exudate Management Primary Dressing: Wound Hydration: Primary Dressing: Exudate Management.
PRODUCTS:
PRODUCTS:
DuoDERM Hydroactive CGF E[ Aquacel Hydrofiber Days UsedM T W T F S S Days UsedM T W T F S S E SAF Gel Kaltostat Dressing Days UsedM T WT F SS Days UsedM T WT F SS D Other Carboflex Odor Days UsedM T WT F SS Days UsedM T WT F SS Secondary Dressing: Moisture Retentive 7 Other Dressing: Days UsedM T W T F S S PRODUCTS: Secondary Dressing: Moisture Retentive Dressing.
El DuoDERM CGF
PRODUCTS:
Days UsedM T W T F S S DuoDERM CGF E DuoDERM Extra Thin Days Used M T W T F S S Days UsedM T W T F S S El DuoDERM Extra Thin Signadress Days UsedM T W T F S S Days Used M T W T F S S l Signadress O Other Days UsedM T W T F SS Days UsedM T WT F SS O Other Days UsedM T W T F S S iti nn 0 7 T Svw' l' I 19- PCT/USOO/01274 Table 2, SECTIONS 4, 5, 6, and 7 4 *GOAL* Reduce devitalized tissue.
Debridement: The suggested topical treatments will facilitate autolytic debridement. Autolytic debridement is usually not recommended for patients with infected wounds or patients at increased risk of infection.
Surgical by MD Nurse Enzymatic Days Used M T W T F S S Autolytic Mechanical Products Used If infection is confirmed, perform Nurse Action 5A. If infection is not confirmed, perform Nurse Action Appropriate medical treatment for infection Evaluate for signs of infection. If not infected, should be initiated or continued. DuoDERM moisture retentive dressing should extend CFG dressings can be continued during the beyond reddened area to protect skin.
treatment of infection at the discretion of the Minimize friction and shear forces to clinician. surrounding skin.
Action Taken and Products Used to Treat Infection 6 7 Provide analgesics. Cover with Relieve Pressure Moisture Retentive Dressings.
Action Taken and Products Used Action Taken and Products Used 'LU\ nn/AIAI A rr~m r n m ~rrl L I/UUUIUI.
Table 2, SECTION 7 Has the patient been screened for Functional limitations nutritional deficiency indicators in the Chewing/swallowing past month. D Mobility Hearing/speech No Yes Rescreen D Vision 4, Monthly D Dexterity Evaluate the patient for presence of any O Altered mental stateO Medical Co of the following nutritional deficiency I Diabetes indicators. Arterial Insufficiency O Cardiovascular disease O Elderly Venous Insufficiency Infection Incontinence D Wound O Gastrointestinal disorder O Systemic Immunosuppression 7 Other 1_ Drug Therapy O Score of<l 8 on Braden Scale O Corticosteroids 7 Poor response to current would Immunosuppressants treatment for past 2-4 weeks O Antitumor agents Recent unintentional weight loss/gain If any of the above is checked, perform Nutrition Assessment.
Example 2 Wound Prevention One example of a method for assessing the status of a patient and derivation of a care plan, or protocol, for wound prevention is as follows. A Patient Risk Assessment Evaluation Sheet (FIG. a type of interactive visual scoring sheet, is completed by a care giver using a variation of the Braden Scale by circling appropriate assessment scores for each risk factor (sensory perception, moisture, activity, mobility, nutrition and friction shear). Second, the Slide Rule Pressure Ulcer Pathway Decision Tool of FIG.
is used as follows: the slide rule is moved to each respective checked score from the Patient Risk Assessment Record (FIG. 4) for each respective risk factor. The arrows downward in the slide rule are followed to select the nurse actions (letters A to X) that correspond with the information contained in the Patient Risk Assessment Record.
Finally, all letters in the a modular wound prevention protocol sheet (also called a Nurse Action Report, FIG. 6) selected from the slide rule are circled. Circled protocols are then tIt ndition WO 00/41714 -21 PCT/US00/01274 followed. Table 3 provides the text of protocols that can be arranged on a single wound prevention protocol sheet, as shown schematically in FIG. 6.
The method of practicing the invention is outlined in the example below. The care giver obtains the Patient Risk Assessment Record (FIG. 4) and the Slide Rule Pressure Ulcer Pathway Decision Tool of FIG. 5, and then examines a patient. The care giver obtains the following assessments: Sensory Perception 3; Moisture 1; Activity 2; Mobility 2; Nutrition 4; Friction Shear 3. After recording this assessment on the Patient Risk Assessment Record (FIG. the care giver follows any arrows in FIG. 4. Specifically, the Moisture grading of 1 points to "See Moisture Chart", the Activity grading of 2 points to "See Activity Chart", the Nurtition grading of 4 has no arrows and the Friction Shear grading of 3 has no arrows.
The care giver the uses the Slide Rule Pressure Ulcer Pathway Decision Tool of FIG. 5, and follows the decision tree for moisture. The first and second sliding cards 22e, 22f of FIG. 5 are displayed in FIG. 5B. Answering all questions, the care giver performs all nurse actions that apply. For instance, if the patient does not suffer urinary or fecal incontinence, but does perspire the care giver would perform Nurse Action F, but not nurse actions A, B, C, D, or E. Further consulting FIG. 5, the care giver slides the sliding card to an Activity rating of 2 and follows the arrows and protocols indicated in the view window (namely Nurse Action K, but not Nurse Action J since the Braden Scale total score is 15 for this patient). The care giver then slides the sliding card until the grade of 3 for nutrition number is indicated in the view window. The care giver then follows protocols indicated in the Nurtition window. For the patient above, given that the patient is only fed orally, Nurse Action P would be performed by the care giver, but not Nurse Actions O or V. The care giver then consults the Friction and Shear section of FIG. 5. Noting that a score of 3 for Friction Shear does not appear with any arrows, no further Nurse Action protocols need be performed. Thus, for the patient of this example, as shown in the Nurse Action Report Sheet (FIG. Nurse Action protocols F, K and P should be performed by the care giver.
lIl nnll A v U I4 22 VPCIlU Table 3: Possible text for modular wound prevention protocol sheet (FIG. 6) S00/01274 Nurse Action Report used.
Circle or check off the appropriate treatments and indicate products Tabie 3, Section 1: Managing Moisture A. If related to tube feeding, lower volume, increase delivery time, decrease osmolality, add filler or add bulking agent.
(Consult dietary plan). If nutritional intake is entreal, determine potential causes of loose stool. Check for impaction. If frequent, apply fecal incontinence pouch. If persistent, obtain order for anti-diarrheal medication.
D. Implement q 2h toileting schedule (waking hours) and offer fluids every 2 hours during waking hours. Cleanse skin promptly with non-drying soap or incontinence skin cleanser, pat dry. Use moisture barrier to protect skin. Use only underpads that wick fluid away from the skin, leaving surface next to skin dry. Cleanse skin, incontinence cleanser or non-drying soap.
D Products used Aloe Vesta Perineal Solution Aloe Vesta Perineal Foam Aloe Vesta Protective Ointment Other B. Cleanse skin promptly and E. Use moisture barrier to protect thoroughly with incontinence skin cleanser surrounding tissue. Pouch heavily draining or non-drying soap and pat dry. wound (Consult ET).
Aloe Vesta Perineal Solution Aloe Vesta Perineal Foam Other Aloe Vesta Protective Ointment Other C. If taking diuretic, schedule in late afternoon. If moisture is due to regular nighttime urinary incontinence, consider one scheduled toileting during the night.
F. Check linens every two hours. Change linens as needed. Bathe daily to remove waste products left by perspiration. Clean skin folds thoroughly, but gently and pat dry. Consider different mattress or support surface if a nonbreathable covering is aggravating problem.
E Septi Soft Body Wash Shampoo 0 Other WO 00/41714 23- PCT/US00/01274 Table 3, Section 2: Activity G. Implement plans for small shift in position.
H. Use pressure reducing chair seating.
Implement q Ih chair repositioning schedule.
O Positioning Cushion I. Teach patient to do lift-offs 15 minutes.
J. When in bed, use foam wedges for lateral position and pillow to bridge sacrum.
Avoid lateral positioning of more than 30 degrees.
L. When in bed. use positioning devices to suspend heels so they do not touch the mattress. Use good positioning to keep knees from iuuching. Avoid elevating HOB more than 30 degrees, except for brief periods.
Positioning Cushion Other M. Use pressure reducing chair seating.
Implement q Ih chair repositioning schedule.
O Positioning Cushion O Other N. Implement q 2h turning schedule. If patient can make purposeful movements, encourage frequent turning/shifts in body position.
Positioning Cushion Pillow Other K. Place pressure reducing surface on bed or chair. Avoid positioning directly on trochanter.
Mattress Overlay Positioning Cushion Other WO 00/41714 24- PCT/USOO/01274 Table 3, Section 3: Managing Nutrition 0. If dietician was not consulted to determine the match between the patient condition, metabolic need, and formula type and amount initiate dietary consult to do so now.
R. Request order for multi-vitamin with Vitamins A, C, and Zinc. Obtain dietary consult if these interventions are not successful within 24 hours. Change diet to reflCci food preferences/habits or to address any problems with chewing or swallowing. Create caloric intake plan and monitor goal achievement.
El Vitamin Supplement Jr. Give protein supplement at bedtime.
o Protein Supplement Q. If the patient is receiving less than optional amount because of high residual volumes in stomach, notify physician and obtain medication orders to decrease gastric retention or obtain orders for parental nutrition.
If the patient is receiving less than the optimal amount because of inadequate ordering or changes in patient's condition, request new orders from physician or dietician.
S. Attempt protein supplement at meals and before bedtime.
Dl Protein Supplement T. Give supplement twice a day.
Protein Supplement D Other U. Initiate physician contact to clarify goals of treatment and/or to examine avenues to improve nutritional intake.
V. Reassess periodically if patient's condition changes.
Wf nl0IA I71 A r rf"wr'7 io/t/i fA4 j -25- r I/UUU/UI/"I Table 3, Section 4: Friction Shear W. Avoid raising HOB>30 degrees.
Use lifting sheet to move patient in bed; do not drag patient across the linens. Use clbovv and 11ec! protectors f11 thicso prominences are exposed to friction. Use a sheepskin under spastic extremities. (Do not place under trunk.) O Positioning Cushion O Heel or Elbow Protectors X. Consider a trapeze, if patient has sufficient upper body strength to assist in moves.
Patient Date: Nurse Physician Notes Further information for products referred to in the above table is listed below.
AQUACEL Hydrofiber: a wound dressing comprising a non-woven pad composed of sodium carboxymethylcellulose fibers. The dressing is highly absorbent and forms a soft gel interacts with wound exudate and forms a soft gel which maintains a moist environment for wound healing.
Arthropad: Tubigrip Arthropad is a wrapping bandage designed to provide lasting, effective support with complete freedom of movement for the patient.
The Tubigrip Arthropad provides tissue support in the management of soft-tissue injuries and general edema and may be used as a pressure dressing.
Carboflex Odor: A sterile non-adhesive dressing with an absorbent wound contact layer (containing Alginate and Hydrocolloid), an activated charcoal pad and a smooth water-resistant top layer.
DuoDERM Extra Thin: highly flexible, control gel formula dressing made for use on dry to lightly exudating wounds. The dressing conforms to the body, WO nn0/4714 mI t J DA S- 26- PI/uSuu/uSZ12 cleans by autolytic debridement and is a highly effective secondary dressing for wound fillers.
DuoDERM Hydroactive Gel: a sterile gel comprising natural hydrocolloids (pectin, sodium carboxymethylcellulose) in a clear, viscous vehicle.
DuoDERM Hydroreactive Gel: a sterile gel composed of natural hydrocolloids (pectin, sodium carboxymethylcellulose) in a clear, viscous vehicle. This product is designed for the management of partial and full-thickness wounds and creates a moist healing environment around a wound which helps to promote the natural autolytic process of debridement.
DuoDERM CGF: is a dressing that interacts with wound exudate to produce a soft mass that enables removal of the dressing with little or no damage to newly formed tissues. The dressing helps isolate the wound against bacterial, viral (HIV-1 and HBV) and other external contamination and can remain in place up to seven days.
Kaltostat: a sterile non-woven dressing of calcium-sodium alginate fiber which can absorb wound exudate or saline and convert from a firm gel/fiber mat. The gel forms a moist, warm environment at the wound interface.
Kalostat Dressing: a highly absorbent calcium alginate dressing derived from natural seaweed designed to absorb exudate and control minor bleeding. The dressing is easy to apply, can remain in place up to seven days, and may be used on moderately to heavily exuding wounds.
Lyofoam Foam Dressing: A polyurethane foam dressing comprising an absorptive hydrophilic contact surface and a secondary outer foam layer through which the aqueous component can be lost by evaporation. The dressing is freely permeable to gases and water vapor but resists strike-through of aqueous solutions and exudate, as the outer layer has hydrophobic properties.
SAF Gel: an alginate containing formulation designed for multiple uses. The gel is indicated for use on chronic and acute wounds such as dry wounds, pressure ulcers (Stages I to IV) and stasis ulcers.
SAF Clens: a wound cleaner that has a dual surfactant formulation designed for cleansing of chronic wounds, including superficial, partial-thickness, dry or nectotic wounds. The wound cleanser is nontoxic, noniritating and comes in norinse formula.
Signadress: a hydrocolloid dressing comprising an inner (wound contact) layer of hydrocolloids contained within an adhesive polymer matrix and an outer layer of polyurethane film. The dressing also has a product identification mark (ConvaTec registered tear drop trademark) and a visible (SignaDRESS) change indicator guide printed on the film backing.
74 WO 00/41714 27- PCT/USOO/0 1274 Sure Press High Compression Bandage and Sure Press Absorbant Padding: The SurePress High Compression Bandage System is comprised of two layers: the SurePress High Compression Bandage, a washable bandage made from highquality blend of cotton-viscose, nylon and LYCRA, and the SurePress Absorbent Padding for use as an underlayer. The System can be used for management of venous leg ulcers and associated conditions, and is contraindicated for the management of arterial and mixed venous/arterial ulcers and legs with an ankle circumference less than 18 cm.
S Tubipad: is made from a layer of polyurethane foam banded to a length of elastic tubular bandage that is used for the protection of heels, elbows and knees.
UNNA-FLEX: is an elastic bandage that provides compression, for instance to improve venous return. The bandage can be self-adherent or in the form of a boot.
One will appreciate that products listed in the table above, or functional equivalents, are commercially available from a variety of vendors.
All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.
While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations in the preferred devices and methods may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the claims that follow.
Claims (10)
1. A method of providing a wound care protocol for a given wound or wound prevention protocol appropriate for a given patient comprising: classifying the wound or patient against a defined scale for a first wound factor, which is defined wound assessment factor or defined wound risk assessment factor to obtain a wound classification; grading the wound or patient against defined scales for one or more second wound factors, which are wound assessment factors or wound risk assessment factors; operating a visual decision tree device to show a decision or visual decision tree corresponding to the wound classification or to a scale for a wound assessment factor, wherein the visual decision tree device identifies one or more components of a treatment protocol for the graded wound factors; and applying the one or more components to the wound or patient.
2. The method of claim 1, wherein the visual decision tree is a mechanical device.
3. The method of claim 1, wherein at least one visual decision tree indicates two or more distinct decisions based on the grade of one or more second wound factors.
4. A method of claim 1 of providing a wound care protocol appropriate for a given wound comprising: 1 classifying the wound against a defined wound classification scheme; :grading the wound against defined scales for one or more second wound 25 assessment factors; :operating visual decision tree device to show a decision or visual decision tree corresponding to the wound classification or to a grade for a wound assessment factor, wherein at least one visual decision tree produced by the device dictates two or more distinct decisions based on the grade of one or more second wound assessment factors, and wherein the visual decision device identifies the one or more components of a treatment protocol for the wound classification and grades of the second wound assessment factor; ••oand applying the one or more components to the wound. Y:AM.,NyKI NO DELETE MR\29681-00 do 29 The method of claim 4, wherein one of the two visual decision tree devices is selected based on wound classification, and the selected visual decision tree device is operated to show a decision or decision tree corresponding to a grade for exudate amount.
6. The method of claim 4, wherein the wound classification scheme grades wounds from non-open or closed wounds, to wounds of various thicknesses, to wound that cannot be graded due to obstructions.
7. The method of claim 1, further comprising: providing an interactive visual scoring sheet on which markers for the available scores for two or more wound factors are displayed; and marking the appropriate score for the two or more wound factors on the interactive visual scoring sheet, wherein the interactive visual scoring sheet contains a marker associated with one or more of the scores identifying an addition to the treatment protocol.
8. A method of identifying a wound care protocol for a given wound or wound prevention protocol appropriate for a given patient comprising: classifying the wound or patient against a defined scale for a first wound factor, which is defined wound assessment factor or defined wound risk assessment factor to obtain a wound classification; ~grading the wound or patient against defined scales for one or more second wound factors, which are wound assessment factors or wound risk assessment factors; operating visual decision tree device to show the visual decision tree corresponding :i 25 to the wound classification or to a scale for a wound assessment factor, wherein at least one visual decision tree dictates two or more distinct decisions based on the grade of one or more second wound factors, and wherein the visual decision tree device identifies at least 0•0 one component of a treatment protocol for the graded wound factors; and .000 marking a pre-defined display of treatment protocols to identify the components of 0 30 a treatment protocol identified by the method. 00.009. The method of claim 8, wherein the method is operated through a graphical user 00 interface on an electronic processor, resulting in a display of treatment protocols that matches a printed display used in manual operations of the method. Y:\MAVINK NO DELETE MR\2951-O0 d0o A visual decision tree device for identifying a wound care protocol for a given wound or wound prevention protocol appropriate for a given patient comprising: a mechanical or electronic device for identifying and displaying one of at least two decisions or visual decision trees based on one or more inputted wound factors according to a defined scale, wherein the visual decision tree device identifies at least one component of a treatment protocol for the wound factors or patient.
11. The visual decision tree device of claim 10 comprising a card on which the decisions or visual decision trees and values for a wound factor are printed; and a sleeve in which the card slides having at least two openings, the first opening alignable separately with separate wound factor values, and the second opening alignable with the distinct decisions on visual decision trees depending on the alignment with the first openings.
12. The visual decision tree device of claim 11 wherein the sliding card comprises markers corresponding for classifying the wound or patient.
13. The visual decision tree device of claim 12 wherein one or more sliding cards shows a visual decision tree and wherein the housing comprises a view window through which one or more visual decision trees corresponding to the wound classification can be viewed. 0o 25 DATED: 6 October 2004 PHILLIPS ORMONDE FITZPATRICK Attorneys for: BRISTOL-MYERS SQUIBB COMPANY Y.AMarNKJ NO DELETE MR29681- 00 do
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11634999P | 1999-01-19 | 1999-01-19 | |
US60/116349 | 1999-01-19 | ||
PCT/US2000/001274 WO2000041714A1 (en) | 1999-01-19 | 2000-01-19 | Method for determining care and prevention pathways for clinical management of wounds |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2968100A AU2968100A (en) | 2000-08-01 |
AU778729B2 true AU778729B2 (en) | 2004-12-16 |
Family
ID=22366641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU29681/00A Ceased AU778729B2 (en) | 1999-01-19 | 2000-01-19 | Method for determining care and prevention pathways for clinical management of wounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1169055A4 (en) |
JP (1) | JP2002534216A (en) |
AU (1) | AU778729B2 (en) |
CA (1) | CA2360247A1 (en) |
NZ (1) | NZ513074A (en) |
WO (1) | WO2000041714A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787363B2 (en) * | 1999-02-22 | 2004-09-07 | Haemoscope Corporation | Method and apparatus for hemostasis and blood management |
ES2697688T3 (en) * | 2014-04-02 | 2019-01-25 | Urgo Lab | Automatic determination of appropriate medical products based on a class of injury |
US10575789B2 (en) | 2014-12-05 | 2020-03-03 | Ricoh Co., Ltd. | Random forest based erythema grading for psoriasis |
CN110598966B (en) * | 2019-03-28 | 2024-01-26 | 中国辐射防护研究院 | Grading method of equipment in risk-guided post-processing facility |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3747847A (en) * | 1972-06-28 | 1973-07-24 | St Joseph S Hospital And Medic | Slide rule guide to intravenous therapy |
DE2428058A1 (en) * | 1974-06-11 | 1976-01-02 | Paul Baettig | Calculation of pharmacokinetic variables - using tables and slide rule with scales of dosage valves regulates drug dose |
US4189634A (en) * | 1976-10-29 | 1980-02-19 | Labove Larry D | Slide rule for hyperalimentation dosage computations |
US4308450A (en) * | 1978-12-22 | 1981-12-29 | Baxter Travenol Laboratories, Inc. | Two-piece slide calculator for determining metabolic requirements and parenteral feeding dosages |
US4820292A (en) * | 1983-10-17 | 1989-04-11 | Enguay Pharmaceutical Associates | Anti-microbial sensitivity test and testing stratum |
US4799500A (en) * | 1986-09-17 | 1989-01-24 | Newbury Renton D | Method of and apparatus for treatment of muscle imbalance |
CA2046802C (en) * | 1990-08-15 | 2007-05-22 | Donald Zane Fortney | Compositions containing protease produced by vibrio and method of use in debridement and wound healing |
US5732397A (en) * | 1992-03-16 | 1998-03-24 | Lincoln National Risk Management, Inc. | Automated decision-making arrangement |
US5299121A (en) * | 1992-06-04 | 1994-03-29 | Medscreen, Inc. | Non-prescription drug medication screening system |
US5265605A (en) * | 1992-06-25 | 1993-11-30 | Afflerbach Denise E | Wound assessment method and apparatus |
US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
US5517405A (en) * | 1993-10-14 | 1996-05-14 | Aetna Life And Casualty Company | Expert system for providing interactive assistance in solving problems such as health care management |
US5706441A (en) * | 1995-06-07 | 1998-01-06 | Cigna Health Corporation | Method and apparatus for objectively monitoring and assessing the performance of health-care providers |
-
2000
- 2000-01-19 WO PCT/US2000/001274 patent/WO2000041714A1/en active IP Right Grant
- 2000-01-19 CA CA002360247A patent/CA2360247A1/en not_active Abandoned
- 2000-01-19 AU AU29681/00A patent/AU778729B2/en not_active Ceased
- 2000-01-19 NZ NZ513074A patent/NZ513074A/en not_active IP Right Cessation
- 2000-01-19 EP EP00908306A patent/EP1169055A4/en not_active Withdrawn
- 2000-01-19 JP JP2000593324A patent/JP2002534216A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2968100A (en) | 2000-08-01 |
WO2000041714A1 (en) | 2000-07-20 |
CA2360247A1 (en) | 2000-07-20 |
EP1169055A4 (en) | 2009-10-21 |
EP1169055A1 (en) | 2002-01-09 |
NZ513074A (en) | 2003-11-28 |
JP2002534216A (en) | 2002-10-15 |
WO2000041714A9 (en) | 2002-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7184963B1 (en) | Method for determining care and prevention pathways for clinical management of wounds | |
Hess | Clinical guide to skin and wound care | |
Bergstrom | Treatment of Pressure Ulcers: Clinical Prctice Guideline | |
Sussman et al. | Wound care: a collaborative practice manual | |
WO2000043046A2 (en) | Wound management system and wound dressing | |
US20040049408A1 (en) | Process for reducing the cost associated with the prevention and treatment of pressure ulcers | |
Ayello | What does the wound say?: why determining etiology is essential for appropriate wound care | |
Clothier | Assessing and managing skin tears in older people | |
AU778729B2 (en) | Method for determining care and prevention pathways for clinical management of wounds | |
Butler | Pediatric skin care: guidelines for assessment, prevention, and treatment. | |
M Abercrombie et al. | Recessive dystrophic epidermolysis bullosa. Part 2: care of the adult patient | |
Jarrett | Prevention and management of neuropathic diabetic foot ulcers | |
Nannery | Coping with lymphedema: A practical guide to understanding, treating, and living with lymphedema | |
Islam | Nurses’ knowledge, attitude, and practice regarding pressure ulcer prevention for hospitalized patients at Rajshahi medical college hospital in Bangladesh | |
Stephen-Haynes | Prevention of skin tears: intrinsic and extrinsic factors | |
Baranoski | Skin tears: staying on guard against the enemy of frail skin | |
Stephen-Haynes | Pressure ulcer risk assessment and prevention | |
Vera | Literature review of kennedy terminal ulcers: Identification, diagnosis, nursing goals, and interventions | |
Myers | Fast Facts for Wound Care Nursing: Practical Wound Management | |
Stevens et al. | Improving the Use of Subscale-Specific Interventions of the Braden Scale Among Nurses | |
Kifer | Fast facts for wound care nursing: practical wound management in a nutshell | |
Corum | Ulcer and wound care: getting to the depth of the tissue | |
for Nursing et al. | Integumentary | |
Reddy et al. | Healing Wounds, Healthy Skin: A Practical Guide for Patients with Chronic Wounds | |
HT | A Comparative Study of Reliability and Validity of the Braden Scale and Norton Scale for Predicting Pressure Ulcer Risk |